18.26
+0.52(+2.93%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
231
First IPO Date
August 01, 2018
| Name | Title | Pay | Year Born |
| Dr. Jinzi Jason Wu Ph.D. | Founder, Chairman & Chief Executive Officer | 59.83M | 1964 |
| Ms. Hejingdao Wu | Senior Vice President of Operations & Executive Director | 3.5M | 1974 |
| Mr. Ming Fai Chung CPA | Company Secretary | 0 | 1979 |
| Dr. George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor | 0 | 1951 |
| Ms. Yuemei Yan | Senior Vice President of Clinical Development Operations | 0 | 1970 |
| Dr. Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery | 0 | 1968 |
| Mr. John P. Gargiulo M.B.A. | Chief Business Officer | 0 | 1960 |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.